A pediatric case links dupilumab therapy for atopic dermatitis with sustained hair regrowth in extensive alopecia areata
Dive into this recent JDD Case Study A single-patient case report describes a 13-year-old male with atopic dermatitis and progressive alopecia areata that advanced to alopecia totalis despite standard therapies. Dupilumab, an interleukin 4 and 13 antagonist approved for atopic dermatitis and asthma, was started for the patient’s atopic disease and was continued as monotherapy. The authors report hair regrowth on the scalp and eyebrows within months and sustained complete regeneration at 17 months after starting dupilumab.
This report highlights a potential role for dupilumab in patients with comorbid atopic dermatitis and alopecia areata, particularly in pediatric practice. The case notes normal hormonal evaluation and prior failure of multiple conventional AA treatments before dupilumab initiation. As a single case, the findings are descriptive and cannot establish efficacy or safety in AA broadly, but they add to emerging observations about biologic modulation and hair regrowth.
For practicing dermatology clinicians and dermatology HCPs, this case may inform discussions when managing patients who have both atopic dermatitis and refractory alopecia areata. Read the full JDD report for treatment timelines, prior therapies, and follow up data, and consider whether dupilumab merits consideration or further study in similar patients.
J Drugs Dermatol. 2026;25(3). doi:10.36849/JDD.9148
Blog write-up assisted by AI
